Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant

• Status: Completed
• Trial end date: 2016-08-29
• Target enrollment: 0
• Participant gender: All

Summary

This study was designed to evaluate the safety and tolerability of HSC835 for clinical use as measured by the absence of graft failure at day 42 in excess of that currently observed with double umbilical cord blood (UCB) transplantation (DUCBT) with non-myeloablative (NMA) conditioning.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals

Criteria

Inclusion Criteria:

• Patients with a diagnosis that qualifies them for UCBT

• Adequate organ function

• Availability of eligible donor material

Exclusion Criteria:

• Pregnancy or breastfeeding women and women of child-bearing potential unless two acceptable forms of contraception are being used

• Human immunodeficiency virus (HIV) infection

• Active infection